They suggest that cytotoxic immune reaction mediated by CD8-positive T cells and PD-L1 expression may predict a better outcome in patients with HER2-positive BC managed with conventional chemotherapy and HER2-blocking therapy [16]. Here, ERBB2 is linked to breast cancer.